Anakinra-Associated Amyloidosis

Sara Alehashemi; Surendra Dasari; Adriana A de Jesus; Edward W Cowen; Chia-Chia Richard Lee; Raphaela Goldbach-Mansky; Ellen D McPhail

doi:10.1001/jamadermatol.2022.2124

Anakinra-Associated Amyloidosis

JAMA Dermatol. 2022 Dec 1;158(12):1454-1457. doi: 10.1001/jamadermatol.2022.2124.

Authors

Sara Alehashemi¹, Surendra Dasari², Adriana A de Jesus¹, Edward W Cowen³, Chia-Chia Richard Lee⁴, Raphaela Goldbach-Mansky¹, Ellen D McPhail⁵

Affiliations

¹ Translational Autoinflammatory Diseases Section, LCIM, National Institute of Allergy, and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
² Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
³ Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland.
⁴ Dermatopathology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
⁵ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.

PMID: 36223107
DOI: 10.1001/jamadermatol.2022.2124

No abstract available

Plain language summary

This case report describes 2 patients with iatrogenic amyloidosis secondary to subcutaneous injections of anakinra to manage neonatal-onset multisystem inflammatory disease.

MeSH terms

Amyloidosis* / chemically induced
Amyloidosis* / diagnosis
Amyloidosis* / drug therapy
Antirheumatic Agents* / adverse effects
Familial Mediterranean Fever* / drug therapy
Humans
Interleukin 1 Receptor Antagonist Protein / adverse effects

Substances

Interleukin 1 Receptor Antagonist Protein
Antirheumatic Agents